Kearns JT - Search Results

1

CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos.

Sala R, Esquer H, Kellett T, Kearns JT, Awolade P, Zhou Q, LaBarbera DV. Sala R, et al. Among authors: kearns jt. Int J Mol Sci. 2024 Aug 6;25(16):8590. doi: 10.3390/ijms25168590. Int J Mol Sci. 2024. PMID: 39201277 Free PMC article.

2

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer.

Clune S, Awolade P, Zhou Q, Esquer H, Matter B, Kearns JT, Kellett T, Akintayo DC, Kompella UB, LaBarbera DV. Clune S, et al. Among authors: kearns jt. Biomed Pharmacother. 2024 Jan;170:116037. doi: 10.1016/j.biopha.2023.116037. Epub 2023 Dec 20. Biomed Pharmacother. 2024. PMID: 38128184 Free PMC article.

3

A regionally tailored epidemiological forecast and monitoring program to guide a healthcare system in the COVID-19 pandemic.

Turk PJ, Anderson WE, Burns RJ, Chou SH, Dobbs TE, Kearns JT, Lirette ST, McCarter MS, Nguyen HM, Passaretti CL, Rose GA, Stephens CL, Zhao J, McWilliams AD. Turk PJ, et al. Among authors: kearns jt. J Infect Public Health. 2024 Jun;17(6):1125-1133. doi: 10.1016/j.jiph.2024.04.014. Epub 2024 Apr 23. J Infect Public Health. 2024. PMID: 38723322 Free article.

4

Is Active Surveillance Too Active?

Kearns JT, Helfand BT. Kearns JT, et al. Curr Urol Rep. 2023 Oct;24(10):463-469. doi: 10.1007/s11934-023-01177-2. Epub 2023 Jul 12. Curr Urol Rep. 2023. PMID: 37436691 Review.

5

Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.

Zhu J, Livasy C, Donahue EE, Symanowski JT, Grigg CM, Brown LC, Matulay JT, Kearns JT, Raghavan D, Burgess EF, Clark PE. Zhu J, et al. Among authors: kearns jt. Transl Androl Urol. 2023 Feb 28;12(2):228-240. doi: 10.21037/tau-22-494. Epub 2023 Feb 7. Transl Androl Urol. 2023. PMID: 36915891 Free PMC article.

6

Systematic review of reported association studies of monogenic genes and bladder cancer risk and confirmation analysis in a large population cohort.

Mian A, Wei J, Shi Z, Rifkin AS, Zheng SL, Glaser AP, Kearns JT, Helfand BT, Xu J. Mian A, et al. Among authors: kearns jt. BJUI Compass. 2022 Dec 7;4(2):156-163. doi: 10.1002/bco2.206. eCollection 2023 Mar. BJUI Compass. 2022. PMID: 36816149 Free PMC article. Review.

7

Moving Prostate Cancer Polygenic Risk Scores from Research Towards Clinical Practice.

Kearns JT, Helfand BT, Xu J. Kearns JT, et al. Eur Urol Focus. 2022 Jul;8(4):913-915. doi: 10.1016/j.euf.2022.08.011. Epub 2022 Aug 31. Eur Urol Focus. 2022. PMID: 36055957 Review.

8

EDITORIAL COMMENT.

Kearns JT. Kearns JT. Urology. 2022 Mar;161:57-58. doi: 10.1016/j.urology.2021.10.044. Urology. 2022. PMID: 35307077 No abstract available.

9

Racial and Socioeconomic Disparities in MRI-Fusion Biopsy Utilization to Assess for Prostate Cancer.

Roebuck E, Sha W, Lu CD, Miller C, Burgess EF, Grigg CM, Zhu J, Gaston KE, Riggs SB, Matulay JT, Clark PE, Kearns JT. Roebuck E, et al. Among authors: kearns jt. Urology. 2022 May;163:156-163. doi: 10.1016/j.urology.2021.11.040. Epub 2022 Jan 5. Urology. 2022. PMID: 34995563

10

Association of 5-Alpha Reductase Inhibitor Use with Prostate Specific Antigen Level at the Time of Urology Referral in a Retrospective Cohort at a Large, Integrated Health Care System.

Kearns JT, Matulay JT, Anderson WE, Hetherington TC, Grigg CM, Zhu J, Gaston KE, Riggs SB, Burgess EF, Clark PE. Kearns JT, et al. Urol Pract. 2021 Nov;8(6):619-623. doi: 10.1097/UPJ.0000000000000257. Epub 2021 Aug 23. Urol Pract. 2021. PMID: 37145508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page